

# Stephen Durham

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/126666/publications.pdf>

Version: 2024-02-01

153  
papers

17,432  
citations

15504

65  
h-index

13771

129  
g-index

159  
all docs

159  
docs citations

159  
times ranked

7267  
citing authors

#	ARTICLE	IF	CITATIONS
1	One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 454-468.	5.7	39
2	Immunotherapy for Allergy. , 2022, , 491-502.		0
3	No apparent impact of incremental dosing on eliciting dose at double-blind, placebo-controlled peanut challenge. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 667-670.	5.7	4
4	Development and validation of combined symptom& medication scores for allergic rhinitis*. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2147-2162.	5.7	32
5	Allergen immunotherapy for long-term tolerance and prevention. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 802-811.	2.9	21
6	Local nasal immunotherapy for allergic rhinitis: A systematic review and meta-analysis. <i>International Forum of Allergy and Rhinology</i> , 2022, 12, 1503-1516.	2.8	10
7	Long-term efficacy of the sublingual and subcutaneous routes in allergen immunotherapy. <i>Allergy and Asthma Proceedings</i> , 2022, 43, 292-298.	2.2	14
8	Placebo effects in allergen immunotherapy& An EAACI Task Force Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 629-647.	5.7	31
9	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 168-190.	5.7	46
10	Repetitive nasal allergen challenge in allergic rhinitis: Priming and Th2-type inflammation but no evidence of remodelling. <i>Clinical and Experimental Allergy</i> , 2021, 51, 329-338.	2.9	22
11	Altered chromatin landscape in circulating T follicular helper and regulatory cells following grass pollen subcutaneous and sublingual immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 663-676.	2.9	34
12	Comparison of nasal allergen challenges with dissolved Timothy grass pollen tablets and aqueous extract. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1543-1545.	5.7	1
13	Anthony Barrington Kay 1939&2020.. <i>Clinical and Experimental Allergy</i> , 2021, 51, 206-208.	2.9	0
14	Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response. <i>Immunity</i> , 2021, 54, 291-307.e7.	14.3	134
15	Innate lymphoid cells: The missing part of a puzzle in food allergy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2002-2016.	5.7	18
16	Passive Prophylactic Administration with a Single Dose of Anti-Fel d 1 Monoclonal Antibodies REGN1908&1909 in Cat Allergen-induced Allergic Rhinitis: A Randomized, Double-Blind, Placebo-controlled Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 23-33.	5.6	40
17	Differential induction of allergen-specific IgA responses following timothy grass subcutaneous and sublingual immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 1061-1071.e11.	2.9	41
18	Technical standards in allergen exposure chambers worldwide & an EAACI Task Force Report. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3589-3612.	5.7	23

#	ARTICLE	IF	CITATIONS
19	The role of allergen-specific IgE, IgG and IgA in allergic disease. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3627-3641.	5.7	100
20	Immunological Responses and Biomarkers for Allergen-Specific Immunotherapy Against Inhaled Allergens. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1769-1778.	3.8	52
21	Allergen-specific IgG+ memory B cells are temporally linked to IgE memory responses. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 180-191.	2.9	46
22	Pollen season is reflected on symptom load for grass and birch pollen-induced allergic rhinitis in different geographic areas—An EAACI Task Force Report. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1099-1106.	5.7	34
23	Is pollen-food syndrome a frequent comorbidity in adults with irritable bowel syndrome?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1780-1783.	5.7	6
24	Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 599083.	4.8	68
25	Allergen Immunotherapy in Children User's Guide. <i>Pediatric Allergy and Immunology</i> , 2020, 31, 1-101.	2.6	169
26	Nasal allergen challenge and environmental exposure chamber challenge: A randomized trial comparing clinical and biological responses to cat allergen. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1585-1597.	2.9	23
27	Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air App. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1672-1688.	5.7	32
28	Hymenoptera Venom Allergy: How Does Venom Immunotherapy Prevent Anaphylaxis From Bee and Wasp Stings?. <i>Frontiers in Immunology</i> , 2019, 10, 1959.	4.8	42
29	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases—Meeting Report (Part 1). <i>Journal of Thoracic Disease</i> , 2019, 11, 3633-3642.	1.4	11
30	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases—Meeting Report (Part 2). <i>Journal of Thoracic Disease</i> , 2019, 11, 4072-4084.	1.4	15
31	Effect of sleep deprivation and exercise on reaction threshold in adults with peanut allergy: A randomized controlled study. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1584-1594.e2.	2.9	84
32	Expert panel process to optimise the design of a randomised controlled trial in chronic rhinosinusitis (the MACRO programme). <i>Trials</i> , 2019, 20, 230.	1.6	4
33	The allergen specificity of allergen immunotherapy—doubt no more. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2054-2056.	5.7	9
34	Clarithromycin and endoscopic sinus surgery for adults with chronic rhinosinusitis with and without nasal polyps: study protocol for the MACRO randomised controlled trial. <i>Trials</i> , 2019, 20, 246.	1.6	11
35	Nasal allergen-neutralizing IgG4 antibodies block IgE-mediated responses: Novel biomarker of subcutaneous grass pollen immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1067-1076.	2.9	90
36	Broad IgG repertoire in patients with chronic rhinosinusitis with nasal polyps regulates proinflammatory IgE responses. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2086-2094.e2.	2.9	27

#	ARTICLE	IF	CITATIONS
37	Mind the gaps: Clinical trial concepts to address unanswered questions in aeroallergen immunotherapy—An NIAID/AHRQ Workshop. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1711-1726.	2.9	20
38	2019 ARIA Care pathways for allergen immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2087-2102.	5.7	140
39	Immunologic mechanisms of a short-course of <i>Lolium perenne</i> peptide immunotherapy: A randomized, double-blind, placebo-controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 738-749.	2.9	35
40	Switch-over from Pharmedgen to Alutard Bee and Wasp venom in the UK. <i>Clinical and Experimental Allergy</i> , 2019, 49, 1645-1646.	2.9	3
41	Duration of allergen immunotherapy for inhalant allergy. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2019, 19, 594-605.	2.3	32
42	Perspectives in allergen immunotherapy: 2019 and beyond. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 3-25.	5.7	113
43	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 864-879.	2.9	103
44	Role of IL-35 in sublingual allergen immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1131-1142.e4.	2.9	82
45	<i>Lolium perenne</i> peptides for treatment of grass pollen allergy: A randomized, double-blind, placebo-controlled clinical trial. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 448-451.	2.9	18
46	Antiapoptotic serine protease inhibitors contribute to survival of allergenic T H 2 cells. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 569-581.e5.	2.9	13
47	Synchronous immune alterations mirror clinical response during allergen immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1750-1760.e1.	2.9	61
48	UK Immunotherapy Study: Reanalysis by a combined symptom and medication score. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1998-1999.e3.	2.9	6
49	Duration of Allergen Immunotherapy for Long-Term Efficacy in Allergic Rhinoconjunctivitis. <i>Current Treatment Options in Allergy</i> , 2018, 5, 275-290.	2.2	58
50	New approaches to allergen immunotherapy. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 293-305.	1.0	54
51	Allergen Immunotherapy for a Teenager with Seasonal Allergic Rhinitis Due to Grass Pollen: Subcutaneous or Sublingual Route?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 52-57.	3.8	4
52	Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 615.	7.4	166
53	Allergen Immunotherapy Clinical Trial Outcomes and Design: Working Toward Harmonization of Methods and Principles. <i>Current Allergy and Asthma Reports</i> , 2017, 17, 18.	5.3	14
54	A Recombinant Fragment of Human Surfactant Protein D Suppresses Basophil Activation and T-Helper Type 2 and B-Cell Responses in Grass Pollen-induced Allergic Inflammation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1526-1534.	5.6	20

#	ARTICLE	IF	CITATIONS
55	Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1485-1498.	2.9	323
56	Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1024-1031.e14.	2.9	376
57	Intradermal grass pollen immunotherapy increases T H 2 and IgE responses and worsens respiratory allergic symptoms. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1830-1839.e13.	2.9	35
58	Applications and mechanisms of immunotherapy in allergic rhinitis and asthma. <i>Therapeutic Advances in Respiratory Disease</i> , 2017, 11, 73-86.	2.6	67
59	S94â€¦Development of assays to assess safety and efficacy of lentiviral gene therapy for cystic fibrosis. , 2017, , .		0
60	Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews. <i>Clinical and Translational Allergy</i> , 2017, 7, 24.	3.2	49
61	Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma. <i>European Respiratory Journal</i> , 2016, 48, 1593-1601.	6.7	58
62	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 367-374.e2.	2.9	128
63	Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1081-1088.e4.	2.9	64
64	IL-25/IL-33â€“responsive TH2 cells characterize nasal polyps with a default TH17 signature in nasal mucosa. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1514-1524.	2.9	78
65	Asthma phenotypes and IgE responses. <i>European Respiratory Journal</i> , 2016, 47, 304-319.	6.7	197
66	Sublingual or subcutaneous immunotherapy for allergic rhinitis?. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 339-349.e10.	2.9	169
67	Short-term subcutaneous grass pollen immunotherapy under the umbrella of antiâ€“IL-4: Aâ€“randomized controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 452-461.e9.	2.9	48
68	A randomised placebo-controlled trial investigating efficacy and mechanisms of low-dose intradermal allergen immunotherapy in treatment of seasonal allergic rhinitis. <i>Efficacy and Mechanism Evaluation</i> , 2016, 3, 1-80.	0.7	1
69	Effect of grass pollen immunotherapy on clinical and local immune response to nasal allergen challenge. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 689-696.	5.7	71
70	Protocol for a randomised, doubleâ€“blind, placeboâ€“controlled study of grass allergen immunotherapy tablet for seasonal allergic rhinitis: time course of nasal, cutaneous and immunological outcomes. <i>Clinical and Translational Allergy</i> , 2015, 5, 43.	3.2	6
71	Immunomodulatory effects of IL-27 on allergen-induced Th2 responses. <i>Journal of Japan Society of Immunology &amp; Allergology in Otolaryngology</i> , 2015, 33, 15-16.	0.0	0
72	IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1249-1256.	2.9	207

#	ARTICLE	IF	CITATIONS
73	Basophil expression of diamine oxidase: A novel biomarker of allergen immunotherapy response. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 913-921.e9.	2.9	101
74	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1089-1090.	2.9	0
75	Severe Persistent Allergic Rhinitis. Inflammation but No Histologic Features of Structural Upper Airway Remodeling. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1431-1439.	5.6	36
76	Peptide-induced immune regulation by a promiscuous and immunodominant CD4T-cell epitope of Timothy grass pollen: a role of Cbl-b and Itch in regulation. <i>Thorax</i> , 2014, 69, 335-345.	5.6	13
77	Grass pollen immunotherapy for treatment of allergic rhinitis. <i>BMJ, The</i> , 2014, 349, g6586-g6586.	6.0	5
78	Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 468-475.e6.	2.9	375
79	Allergen-specific IgE is not detectable in the bronchial mucosa of nonatopic asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1770-1772.e11.	2.9	24
80	Seasonal increases in peripheral innate lymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 1193-1195.e4.	2.9	166
81	Influence of seasonal exposure to grass pollen on local and peripheral blood IgE repertoires in patients with allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 604-612.	2.9	55
82	Sublingual immunotherapy: World Allergy Organization position paper 2013 update. <i>World Allergy Organization Journal</i> , 2014, 7, 6.	3.5	395
83	Specific immunotherapy modifies allergen-specific CD4+ T-cell responses in an epitope-dependent manner. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 872-879.e7.	2.9	110
84	Basophil Activation Test Using Recombinant Allergens: Highly Specific Diagnostic Method Complementing Routine Tests in Wasp Venom Allergy. <i>PLoS ONE</i> , 2014, 9, e108619.	2.5	34
85	Grass pollen nasal challenge is associated with increases in Th2 cytokines, Eotaxin, MDC and IL6 in nasal fluid. <i>Clinical and Translational Allergy</i> , 2013, 3, P29.	3.2	2
86	Grading local side effects of sublingual immunotherapy for respiratory allergy: Speaking the same language. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 93-98.	2.9	144
87	Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1543-1556.	3.1	68
88	Protocol for a double-blind randomised controlled trial of low dose intradermal grass pollen immunotherapy versus a histamine control on symptoms and medication use in adults with seasonal allergic rhinitis (PollenLITE). <i>Clinical and Translational Allergy</i> , 2013, 3, 27.	3.2	6
89	IL-35+ Regulatory T Cells Suppress Grass Pollen-Driven Th2 Responses and Are Induced Following Grass Pollen-Specific Sublingual Immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, AB146.	2.9	3
90	Cell-free detection of allergen-IgE cross-linking with immobilized phase CD23: Inhibition by blocking antibody responses after immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 1003-1005.e4.	2.9	51

#	ARTICLE	IF	CITATIONS
91	Allergen Immunotherapy and Tolerance. <i>Allergology International</i> , 2013, 62, 403-413.	3.3	88
92	Immunotherapy Is Allergen-Specific: A Double-Blind Trial of Mite or Timothy Extract in Mite and Grass Dual-Allergic Patients. <i>International Archives of Allergy and Immunology</i> , 2012, 158, 63-70.	2.1	28
93	Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes. <i>Journal of Immunological Methods</i> , 2012, 384, 25-32.	1.4	84
94	Allergen immunotherapy for allergic respiratory diseases. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1499-1512.	3.3	38
95	EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. <i>Clinical and Translational Allergy</i> , 2012, 2, 20.	3.2	97
96	SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 717-725.e5.	2.9	447
97	Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 918-924.e1.	2.9	37
98	Cochrane Review: Sublingual immunotherapy for treating allergic conjunctivitis. <i>Evidence-Based Child Health: A Cochrane Review Journal</i> , 2012, 7, 1041-1154.	2.0	2
99	Allergen Immunotherapy: A Centenary Celebration. <i>World Allergy Organization Journal</i> , 2011, 4, 104-106.	3.5	13
100	Mechanisms of Sublingual Immunotherapy. <i>Immunology and Allergy Clinics of North America</i> , 2011, 31, 191-209.	1.9	26
101	Allergen-specific immunotherapy for respiratory allergies: From meta-analysis to registration and beyond. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 30-38.	2.9	168
102	The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: A Global Allergy and Asthma European Network (GA2LEN) article. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 49-56.e11.	2.9	42
103	One hundred years of allergen immunotherapy: Time to ring the changes. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 3-7.	2.9	57
104	Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 509-516.e5.	2.9	299
105	Serum Immunologic Markers for Monitoring Allergen-Specific Immunotherapy. <i>Immunology and Allergy Clinics of North America</i> , 2011, 31, 311-323.	1.9	37
106	Long-term clinical and immunological effects of allergen immunotherapy. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2011, 11, 586-593.	2.3	76
107	Systematic reviews of sublingual immunotherapy (SLIT). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2011, 66, 740-752.	5.7	234
108	Sublingual immunotherapy for treating allergic conjunctivitis. <i>The Cochrane Library</i> , 2011, , CD007685.	2.8	31

#	ARTICLE	IF	CITATIONS
109	Cochrane review: Allergen injection immunotherapy for seasonal allergic rhinitis. Evidence-Based Child Health: A Cochrane Review Journal, 2010, 5, 1279-1379.	2.0	3
110	Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. Journal of Allergy and Clinical Immunology, 2010, 125, 131-138.e7.	2.9	311
111	Sublingual Immunotherapy: World Allergy Organization Position Paper 2009. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1-59.	5.7	316
112	Mechanisms of Sublingual Immunotherapy. Journal of Asthma, 2009, 46, 322-334.	1.7	77
113	Sub-Lingual Immunotherapy. World Allergy Organization Journal, 2009, 2, 233-281.	3.5	100
114	Grazax: sublingual immunotherapy for grass pollen allergy. The Prescriber, 2008, 19, 47-50.	0.3	2
115	Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. Journal of Allergy and Clinical Immunology, 2008, 121, 512-518.e2.	2.9	192
116	Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. Journal of Allergy and Clinical Immunology, 2008, 121, 1120-1125.e2.	2.9	289
117	Grass pollen immunotherapy induces Foxp3-expressing CD4+CD25+ cells in the nasal mucosa. Journal of Allergy and Clinical Immunology, 2008, 121, 1467-1472.e1.	2.9	285
118	Sublingual immunotherapy: what have we learnt from the "big trials"? Current Opinion in Allergy and Clinical Immunology, 2008, 8, 577-584.	2.3	42
119	Mechanisms of immunotherapy. Drugs of Today, 2008, 44 Suppl B, 93-4.	1.1	3
120	Grass Pollen Immunotherapy Induces an Allergen-Specific IgA2 Antibody Response Associated with Mucosal TGF- $\beta$ 2 Expression. Journal of Immunology, 2007, 178, 4658-4666.	0.8	216
121	Allergen injection immunotherapy for seasonal allergic rhinitis. The Cochrane Library, 2007, , CD001936.	2.8	385
122	Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma. Journal of Allergy and Clinical Immunology, 2007, 119, 213-218.	2.9	222
123	Allergic Rhinitis and its Impact on Asthma update: Allergen immunotherapy. Journal of Allergy and Clinical Immunology, 2007, 119, 881-891.	2.9	251
124	Tradition and innovation: Finding the right balance. Journal of Allergy and Clinical Immunology, 2007, 119, 792-795.	2.9	8
125	Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. Journal of Allergy and Clinical Immunology, 2007, 120, 688-695.	2.9	122
126	Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: A double-blind, randomised study. Quality of Life Research, 2007, 16, 191-201.	3.1	55



#	ARTICLE	IF	CITATIONS
127	Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 319-325.	2.9	353
128	Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 802-809.	2.9	470
129	Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 118, 434-440.	2.9	415
130	Allergen immunotherapy (desensitisation) for allergic diseases. <i>Clinical Medicine</i> , 2006, 6, 348-351.	1.9	15
131	The IgE-facilitated allergen binding (FAB) assay: Validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. <i>Journal of Immunological Methods</i> , 2006, 317, 71-79.	1.4	138
132	IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: Effect of immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 116, 73-79.	2.9	99
133	Grass Pollen Immunotherapy Induces Mucosal and Peripheral IL-10 Responses and Blocking IgG Activity. <i>Journal of Immunology</i> , 2004, 172, 3252-3259.	0.8	496
134	Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 112, 915-922.	2.9	266
135	Sublingual immunotherapy for allergic rhinitis. , 2003, , CD002893.		229
136	Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 111, 1255-1261.	2.9	486
137	Increases in Allergen-Specific IgE in BAL after Segmental Allergen Challenge in Atopic Asthmatics. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 22-26.	5.6	85
138	NHS allergy services in the UK: proposals to improve allergy care. <i>Clinical Medicine</i> , 2002, 2, 122-127.	1.9	21
139	Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. <i>Immunology</i> , 2002, 105, 56-62.	4.4	132
140	Local expression of $\mu$ germline gene transcripts and RNA for the $\mu$ heavy chain of IgE in the bronchial mucosa in atopic and nonatopic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 107, 686-692.	2.9	161
141	Grass pollen immunotherapy: Symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 107, 971-976.	2.9	115
142	Long-Term Clinical Efficacy of Grass-Pollen Immunotherapy. <i>New England Journal of Medicine</i> , 1999, 341, 468-475.	27.0	1,256
143	Allergen Immunotherapy: Therapeutic Vaccines for Allergic Diseases. <i>Annals of Allergy, Asthma and Immunology</i> , 1998, 81, 401-405.	1.0	302
144	Immunologic changes associated with allergen immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 102, 157-164.	2.9	321

#	ARTICLE	IF	CITATIONS
145	IL-13 mRNA and Immunoreactivity in Allergen-induced Rhinitis: Comparison with IL-4 Expression and Modulation by Topical Glucocorticoid Therapy. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1997, 17, 17-24.	2.9	77
146	Local IgE Production in Nasal Allergy. <i>International Archives of Allergy and Immunology</i> , 1997, 113, 128-130.	2.1	65
147	Enhanced expression of high-affinity IgE receptor (Fc $\epsilon$ RI) $\alpha$ chain in human allergen-induced rhinitis with co-localization to mast cells, macrophages, eosinophils, and dendritic cells. <i>Journal of Allergy and Clinical Immunology</i> , 1997, 100, 78-86.	2.9	74
148	Localization and up-regulation of Mucin (MUC2) gene expression in human nasal biopsies of patients with cystic fibrosis. <i>Journal of Pathology</i> , 1997, 181, 305-310.	4.5	30
149	Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon- $\gamma$ . <i>Journal of Allergy and Clinical Immunology</i> , 1996, 97, 1356-1365.	2.9	383
150	Human eosinophils express messenger RNA encoding RANTES and store and release biologically active RANTES protein. <i>European Journal of Immunology</i> , 1996, 26, 70-76.	2.9	84
151	Secretion of the eosinophil-active cytokines interleukin-5, granulocyte/macrophage colony-stimulating factor and interleukin-3 by bronchoalveolar lavage CD4+ and CD8+ T cell lines in atopic asthmatics, and atopic and nonatopic controls. <i>European Journal of Immunology</i> , 1995, 25, 2727-2731.	2.9	108
152	Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. <i>Nature Medicine</i> , 1995, 1, 39-46.	30.7	736
153	Sublingual immunotherapy for allergic rhinitis. <i>The Cochrane Library</i> , 0, , .	2.8	86